CroíValve is an early stage medical device company focused on developing a minimally invasive device for the treatment of tricuspid regurgitation. It is based in Dublin, Ireland and combines significant clinical, technical and commercial experience.
Lucy O'Keeffe: CEO
Lucy has extensive experience leading medical device development programs. She worked as a cross-functional lead at Medtronic, managing R&D
programs from concept to launch, including an early transcatheter aortic
program. Additionally, she worked in Nypro Healthcare, managing multiple complex, cross-functional, global
projects developing drug delivery devices for top tier pharmaceutical clients and in a CRO, ICON PLC, where she developed an understanding of clinical trials.
She holds a degree in Mechanical Engineering
from University College Dublin, a PhD in Biomedical Engineering from University
of Limerick and a Diploma in Project Management from University College Cork.
Dr Martin Quinn:
Martin is a consultant Interventional Cardiologist in St
Vincent’s University Hospital and Blackrock Clinic with in-depth knowledge of
the disease state and percutaneous methodologies to treat cardiovascular
disease. He completed an interventional cardiology fellowship at the Cleveland
Clinic, and has led the development of percutaneous valve therapies in Ireland,
performing the first TAVI implant in Ireland in 2008. He acts as an expert reviewer
for the Irish Health Products Regulatory Authority. He has filed multiple
patents for cardiovascular devices and first patented the CroíValve concept in
He studied medicine at UCD, completed an MSc in
Cardiology at Trinity College and was awarded a PhD in Thrombosis for his
research on platelet biology and thrombosis at the Royal College of Surgeons in
Ireland in 2001.
Dr Ivan Vesely: CTO
Ivan is a structural heart device innovator, expert in
heart valve design and tissue biomechanics. He was founder and CTO/CSO of ValveXchange,
an early stage company focusing on minimally invasive aortic heart valve
surgery. He invented the technology and led the company from concept
development, through pre-clinical testing, to clinical implants, completing 45
successful surgical procedures. Previously he was an Endowed Professor of
Bioengineering and Cardiothoracic Surgery at the University of Southern
California and he established the Heart Valve Laboratory at Cleveland Clinic,
building it over 10 years into the most well-funded, highly recognized heart
valve research program in the U.S. Before joining CroiValve in late 2018, he
has worked as a product expert with BSI Americas - a CE Marking Notified Body.
He has a BS in Electrical
Engineering and a Ph.D. in Biophysics from The University of Western Ontario,
Board of Directors
Bernard Collins: Chairman
As the chairman of CroiValve, Dr Bernard Collins brings a wealth of business experience. He serves on the Board of Directors of several U.S. and Irish life-science companies. Prior to forming Lifemed, his consultancy company, Dr Collins served for 10 years as Vice President of International Operations at Boston Scientific Corporation and before this held senior executive positions in life-science companies including Baxter Corporation. His general management experience in the medical device and health care industry spans start-ups, turnarounds, leveraged buyouts and IPOs for both large and small businesses.
Dr Collins holds a BA Honors in Applied Industrial Psychology/Business from University College Cork, Ireland and an honorary Doctorate in Law from the National University of Ireland Galway. He is a recipient of the prestigious RDS Gold Medal for Industry in recognition of his extraordinary contribution to the development of the biomedical industry in Ireland
Robert (Chip) Hance
Robert (Chip) Hance is the former CEO of Creganna Medical,
an Ireland-based medical device company with over 2,000 employees worldwide
that was acquired by TE Connectivity in 2016. In 2012-13, Chip was an
Entrepreneur-in-Residence at the Center for Devices and Radiological Health
within the United States Food and Drug Administration (FDA), where he co-led
the Innovation Pathway team focused on streamlining aspects of medical device
clinical trials in the U.S.
Prior to his FDA experience, Chip was most recently President
of Abbott Vascular, the cardiovascular device division of Abbott. Over a decade
in interventional cardiology at Abbott Vascular, he led the organization to
global leadership in the drug-eluting stent market through the launch of Xience
in the U.S., Japan and China. Chip also led the development and CE marking of
Absorb, a bioabsorbable scaffold for the treatment of coronary disease and the
acquisition and international expansion of Mitraclip, a percutaneous mitral
valve repair device.
Chip earned a bachelor’s degree in Chemical Engineering from
the Massachusetts Institute of Technology and a master’s degree in Business
Administration from Harvard Business School.
Helen has over 25
years’ experience in the Medical device industry including as Chief Executive
Officer of Creganna Medical and Product Development and Research roles at Medtronic
and Covidien. She has demonstrated the ability to scale, including acquiring
and integrating companies, establishing strategic joint ventures and raising of
debt and equity financing.
She now works with
Irish companies supporting them to scale. She serves as a director for Enterprise
Ireland and a number of early stage Medical device companies and charities. She
acts as an advisor to Atlantic Bridge Ventures University Bridge Fund and is
currently the Chair of the Implementation Group on Police Reform having recently
served as a member of the Commission on the Future of Policing in Ireland.
Helen has a Bachelor of Engineering from NUI
Galway, a Masters in Project Management from UL, and has completed a Senior
Executive Programme at Stanford University.
Helen has received an honorary Doctorate from NUIG and is a fellow of
the Institute of Engineers of Ireland and a member of the Irish Academy of